Medacta reports second-half beat, maintains 2026 guidance By Investing.com

Medacta reported H2 adjusted EBITDA of EUR92m (3% ahead of consensus) and adjusted EBIT of EUR52m (1% ahead), with group sales up 17% in constant currency. Free cashflow to equity improved to -EUR3m from -EUR8m in 2024. Management guided 2026 revenue growth of 10-14% in constant currency and a 50bps constant-currency EBITDA margin expansion; updated mid-term revenue growth for 2024-27 was raised to 12-15% (from 10-14%). UBS notes 2026 guidance aligns with consensus at the midpoint when accounting for FX margin headwinds.

Analysis

Medacta’s story is less about a binary beat/miss and more about optionality in margin leverage as revenue scales — the next 12 months will reveal whether operating expense control was structural or one-off timing. FX volatility is the most actionable swing factor: a sustained 5–8% move in major cross rates (EUR vs USD/CHF) will swing reported margins by tens to low‑hundreds of basis points, easily overwhelming modest organic margin improvements.

A softer-than-modeled gross margin alongside better opex control hints at a mix shift or transient cost pressure (raw materials, manufacturing routing) that management is masking via SG&A discipline; if mix normalizes toward higher‑margin implants/services, operating leverage can lift margins materially in 2026–27. The mid‑cycle revenue re-acceleration implies investments (sales hires, distribution expansion or tuck-ins) that will compress near-term FCF but set up 2–3 year incremental ROIC expansion if OR volumes remain stable or improve.

Key risks and catalysts cluster around three items with clear time windows: near-term (0–3 months) FX moves and 1Q/2Q trading updates; medium (3–12 months) evidence of gross margin normalization and conversion of higher top-line into EBITDA; longer-term (12–36 months) realization of mid-term revenue targets and associated cash conversion. A re-rating requires visible gross margin recovery plus FX stability — absent that, the story is earnings quality/working‑capital sensitive rather than pure growth.

Key Decisions for Investors

• Long MOVE (Medacta, SIX:MOVE) — accumulate on pullback of 8–12% intraday or place a limit ladder over 2–4 weeks. Timeframe: 12 months. Rationale: asymmetric upside from 12–15% revenue trajectory plus operating leverage if gross margin normalizes; target +30–40% upside vs downside ~25% if FX and gross margin remain adverse. Suggested risk control: 20% stop‑loss from entry or hedge with 6–9 month puts at 20–25% OTM.
• Pair trade: Long MOVE / Short ZBH (Zimmer Biomet) or SYK (Stryker) — size 1:1 to isolate company execution vs elective surgery cycle. Timeframe: 6–12 months. Rationale: isolates Medacta’s margin recovery and commercial upside vs larger peers where multiple compression is tied to macro elective volume risk; expected relative outperformance 15–25% if Medacta converts guidance, downside symmetric if surgical volumes fall.
• Options play for asymmetric risk: Buy 12–15 month CALLS on MOVE ~25–30% OTM to express convexity to margin re-rating, funded by selling 3–6 month OTM puts in size you’d be willing to own at strike. Timeframe: 12 months. Risk/Reward: limited premium risk vs potential 3x+ payoff if guidance execution and FX tailwinds materialize; assignment risk if short puts exercised — size to maximum 50% of intended long equity exposure.
• Event hedge: If EUR weakens >5% within 3 months, trim longs and rotate into consumables-heavy names with USD‑dominated revenue (e.g., SN, ZBH) to protect margins. Timeframe: tactical (days–weeks). Rationale: FX shock is the highest probability near-term de‑rating catalyst; this rule reduces downside 30–50% versus holding unhedged.